Alice's questions to Mineralys Therapeutics Inc (MLYS) leadership • Q4 2024
Question
Alice, on behalf of Charlie Yang at Bank of America, asked about safety and tolerability expectations for the pivotal readouts and how lorundrostat aims to differentiate from MRAs, questioning if a cleaner safety profile could be a commercial win even with slightly less efficacy.
Answer
Executive Jon Congleton highlighted that as an aldosterone synthase inhibitor (ASI), lorundrostat targets the root cause of elevated aldosterone, differentiating it from MRAs and avoiding androgenic side effects, while also expecting a more modest impact on potassium. Chief Medical Officer Dr. David Rodman added that the rigorous design of the ADVANCE-HTN trial will establish a new benchmark for efficacy in this patient population, making direct comparisons to older MRA studies difficult.